News
Zacks.com on MSN10h
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug ...
Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks Jim Cramer reflected on. When asked about the stock during the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback